Literature DB >> 24980076

Efficacy of revascularization for critical limb ischemia in patients with end-stage renal disease.

S Yamamoto1, A Hosaka2, H Okamoto1, K Shigematsu1, T Miyata1, T Watanabe1.   

Abstract

OBJECTIVE: To evaluate the outcomes of surgical revascularization for critical limb ischemia in patients with end-stage renal disease (ESRD). PATIENTS AND METHODS: From 2004 to 2010, 184 patients with 213 critically ischaemic limbs caused by arteriosclerosis were admitted to The University of Tokyo Hospital. The outcomes of primarily surgical revascularization-based treatments were retrospectively compared in patients with ESRD (ESRD group: 79 patients, 101 limbs) and without ESRD (non-ESRD group: 105 patients, 112 limbs) during the same period.
RESULTS: Arterial reconstruction was performed on 56 limbs in 46 patients in the ESRD group and 78 limbs in 73 patients in the non-ESRD group (55% vs. 70%; p = .03). Major amputation was performed in 6 of 48 limbs with patent grafts in the ESRD group because of uncontrolled infection or progression of necrosis. The limb salvage rate after arterial reconstruction was significantly lower in the ESRD group than in the non-ESRD group (p = .0019). The postoperative survival rate was lower in the ESRD group than in the non-ESRD group, although this difference was not significant (p = .052). Associated cardiovascular disease and systemic infection were the most frequent causes of death in the ESRD group. There was no significant difference in graft patency between the two groups after distal bypass surgery; however, the limb salvage rate was significantly lower in the ESRD group than in the non-ESRD group (p = .03).
CONCLUSIONS: Critical limb ischemia associated with ESRD has a poor prognosis. Infection control is particularly important for achievement of good treatment outcomes.
Copyright © 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Arterial reconstruction; Critical limb ischemia; End-stage renal disease; Limb salvage

Mesh:

Year:  2014        PMID: 24980076     DOI: 10.1016/j.ejvs.2014.05.019

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  5 in total

1.  7(th) Asian PAD Workshop.

Authors: 
Journal:  Ann Vasc Dis       Date:  2016-05-25

2.  Nationwide Trends in Hospital Outcomes and Utilization After Lower Limb Revascularization in Patients on Hemodialysis.

Authors:  Pranav S Garimella; Poojitha Balakrishnan; Ashish Correa; Priti Poojary; Narender Annapureddy; Kinsuk Chauhan; Achint Patel; Shanti Patel; Ioannis Konstantinidis; Lili Chan; Shiv Kumar Agarwal; Bernard G Jaar; Umesh Gidwani; Kunihiro Matsushita; Girish N Nadkarni
Journal:  JACC Cardiovasc Interv       Date:  2017-10-23       Impact factor: 11.195

3.  Comparison of Clinical Outcomes after Surgical and Endovascular Revascularization in Hemodialysis Patients with Critical Limb Ischemia.

Authors:  Tatsuya Shiraki; Osamu Iida; Mitsuyoshi Takahara; Yoshimitsu Soga; Shinsuke Mii; Jin Okazaki; Sosei Kuma; Terutoshi Yamaoka; Daisuke Kamoi; Yoshiaki Shintani; Toshinobu Ishikawa; Ikuro Kitano; Masaaki Uematsu
Journal:  J Atheroscler Thromb       Date:  2016-10-13       Impact factor: 4.928

4.  Impact of Chronic Renal Failure on Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Artery Disease: Subgroup Analysis from Zilver PTX Post-Market Surveillance Study in Japan.

Authors:  Yukihisa Ogawa; Hiroyoshi Yokoi; Takao Ohki; Kimihiko Kichikawa; Masato Nakamura; Kimihiro Komori; Shinsuke Nanto; Erin E O'Leary; Aaron E Lottes; Alan T Saunders; Michael D Dake
Journal:  Cardiovasc Intervent Radiol       Date:  2017-05-09       Impact factor: 2.740

5.  Association of chronic kidney disease with perioperative outcomes following acute lower limb revascularization.

Authors:  Nam Yong Cho; Russyan Mark Mabeza; Cory Lee; Arjun Verma; Josef Madrigal; Joseph Hadaya; Christian de Virgilio; Peyman Benharash
Journal:  Surg Open Sci       Date:  2022-05-11
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.